Cargando…

Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial

BACKGROUND AND THE PURPOSE OF THE STUDY: Diabetic neuropathy is the most common diabetic complication that often is accompanied by significant morbidity, mortality and economic burden. The purpose of this study was evaluation of effect of Semelil (ANGIPARS™), a new herbal drug for treatment of diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakhshayeshi, S., Madani, SP., Hemmatabadi, M., Heshmat, R., Larijani, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232074/
https://www.ncbi.nlm.nih.gov/pubmed/22615641
_version_ 1782218318446329856
author Bakhshayeshi, S.
Madani, SP.
Hemmatabadi, M.
Heshmat, R.
Larijani, B.
author_facet Bakhshayeshi, S.
Madani, SP.
Hemmatabadi, M.
Heshmat, R.
Larijani, B.
author_sort Bakhshayeshi, S.
collection PubMed
description BACKGROUND AND THE PURPOSE OF THE STUDY: Diabetic neuropathy is the most common diabetic complication that often is accompanied by significant morbidity, mortality and economic burden. The purpose of this study was evaluation of effect of Semelil (ANGIPARS™), a new herbal drug for treatment of diabetic foot ulcers or diabetic peripheral neuropathy. METHODS: In this double blind clinical trial, 49 type 2 diabetes patients with different degrees of neuropathy were evaluated in two groups (ANGIPARS™ and placebo groups). All patients were assessed at the start and 12 weeks after treatment, with laboratory tests, United Kingdom screening test, Michigan neuropathy screening score, Michigan diabetic neuropathy score, vibration perception thresholds, nerve conduction study, monofilament test and visual analog scale. RESULTS: Michigan diabetic neuropathy score was decreased notably in ANGIPARS™ group. In the nerve conduction study, appropriate meaningful changes were observed in the distal latency and amplitude in the motor Ulnar nerve in ANGIPARS™ group. CONCLUSION: The results showed limited evidence of efficacy of ANGIPARS™ in diabetic neuropathy treatment and more studies with a larger sample size and longer duration are required.
format Online
Article
Text
id pubmed-3232074
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-32320742012-05-21 Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial Bakhshayeshi, S. Madani, SP. Hemmatabadi, M. Heshmat, R. Larijani, B. Daru Original Article BACKGROUND AND THE PURPOSE OF THE STUDY: Diabetic neuropathy is the most common diabetic complication that often is accompanied by significant morbidity, mortality and economic burden. The purpose of this study was evaluation of effect of Semelil (ANGIPARS™), a new herbal drug for treatment of diabetic foot ulcers or diabetic peripheral neuropathy. METHODS: In this double blind clinical trial, 49 type 2 diabetes patients with different degrees of neuropathy were evaluated in two groups (ANGIPARS™ and placebo groups). All patients were assessed at the start and 12 weeks after treatment, with laboratory tests, United Kingdom screening test, Michigan neuropathy screening score, Michigan diabetic neuropathy score, vibration perception thresholds, nerve conduction study, monofilament test and visual analog scale. RESULTS: Michigan diabetic neuropathy score was decreased notably in ANGIPARS™ group. In the nerve conduction study, appropriate meaningful changes were observed in the distal latency and amplitude in the motor Ulnar nerve in ANGIPARS™ group. CONCLUSION: The results showed limited evidence of efficacy of ANGIPARS™ in diabetic neuropathy treatment and more studies with a larger sample size and longer duration are required. Tehran University of Medical Sciences 2011 /pmc/articles/PMC3232074/ /pubmed/22615641 Text en © 2011 Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Bakhshayeshi, S.
Madani, SP.
Hemmatabadi, M.
Heshmat, R.
Larijani, B.
Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
title Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
title_full Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
title_fullStr Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
title_full_unstemmed Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
title_short Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial
title_sort effects of semelil (angipars™) on diabetic peripheral neuropathy: a randomized, double-blind placebo-controlled clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232074/
https://www.ncbi.nlm.nih.gov/pubmed/22615641
work_keys_str_mv AT bakhshayeshis effectsofsemelilangiparsondiabeticperipheralneuropathyarandomizeddoubleblindplacebocontrolledclinicaltrial
AT madanisp effectsofsemelilangiparsondiabeticperipheralneuropathyarandomizeddoubleblindplacebocontrolledclinicaltrial
AT hemmatabadim effectsofsemelilangiparsondiabeticperipheralneuropathyarandomizeddoubleblindplacebocontrolledclinicaltrial
AT heshmatr effectsofsemelilangiparsondiabeticperipheralneuropathyarandomizeddoubleblindplacebocontrolledclinicaltrial
AT larijanib effectsofsemelilangiparsondiabeticperipheralneuropathyarandomizeddoubleblindplacebocontrolledclinicaltrial